Psychiatric Research Unit, Child and Adolescent Psychiatric Department, Region Zealand Psychiatry, Region Zealand, Denmark.
Psychiatric Research Unit, Region Zealand Psychiatry, Region Zealand, Denmark.
JAMA. 2016 May 10;315(18):2009-10. doi: 10.1001/jama.2016.3611.
Is treatment with methylphenidate associated with benefits or harms for children and adolescents with attention-deficit/hyperactivity disorder (ADHD)?
Methylphenidate is associated with improvement in ADHD symptoms, general behavior, and quality of life; however, due to the very low quality of the evidence, the magnitude of the associated improvement is uncertain. Methylphenidate was associated with an increased risk of nonserious adverse events. There are too few data to assess the association with serious adverse events.
哌醋甲酯治疗是否对患有注意缺陷多动障碍(ADHD)的儿童和青少年有益或有害?
哌醋甲酯可改善 ADHD 症状、一般行为和生活质量;但由于证据质量极低,相关改善的程度不确定。哌醋甲酯与非严重不良事件的风险增加相关。评估与严重不良事件的关联的数据太少。